Tivantinib (ARQ 197) vs Placebo in patients with Hepatocellular Carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase 2 trialF. T. Kolligs,J. Trojan, P. Buggisch, G. Gerken,R. M. Schmid,E. N. de Toni, S. Zeuzem,C. Porta,I Borbath, L. Rimassa,B. Daniele, S. Salvagni,J-L van Laethem,H. van Vlierberghe,A. Gasbarrini, M. Lencioni,R. von Roemeling, G. Abbadessa,B. Schwartz, A. SantoroONKOLOGIE（2012）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
